Abstract
3’-O-Retinoyl-5-fluoro-2’-deoxyuridine (RFUdR) is a putative dual-acting, mutually-masking (DAMM) prodrug for the treatment of cancer. As part of the proof of principle for the DAMM concept, the concentrations of RFUdR and its post-hydrolysis active metabolites, 5-fluoro-2’-deoxyuridine (FUdR) and all-trans-retinoic acid (RA), were determined in plasma and selected tissues following either bolus intravenous (i.v.; 12.5 μmol/kg) or oral (p.o.; 13.7 μmol/kg) doses of RFUdR to mice bearing EMT6 murine mammary tumors. The concentrations of RFUdR and its primary metabolites were measured by high-performance liquid chromatography. A three compartment model provided the best fit for plasma RFUdR after an i.v. bolus, whereas FUdR and RA data were best fit by a one compartment model. The terminal half-life of RFUdR in plasma was 9 hours. The AUC of RFUdR in tumor (3400 μmol/Lmin) was estimated to be about 4- fold higher than its AUC in the plasma (809±241 μmol/Lmin). A short-duration, saturated elimination phase for RFUdR was observed in both liver and kidney following an i.v. bolus. Neither unchanged RFUdR nor RA was detected in urine. The high bioavailability (~90%) following oral dosing with RFUdR indicates that this DAMM prodrug may be suitable for oral dosing to deliver FUdR and RA for cancer chemotherapy.
Keywords: Pharmacokinetics, dual-acting, mutually-masking prodrug (DAMM), 3’-O-retinoyl-5-fluoro-2’-deoxyuridine (RFUdR), 5-fluoro-2’-deoxyuridine (FUdR), all-trans-retinoic acid (RA).
Current Drug Delivery
Title:Pharmacokinetics of 3’-O-Retinoyl-5-fluoro-2’-deoxyuridine (RFUdR), a Dual Acting Mutually Masking Prodrug, and Its Metabolites in Tumor Bearing Mice
Volume: 10 Issue: 5
Author(s): Zuping Xia, Edward E. Knaus and Leonard I. Wiebe
Affiliation:
Keywords: Pharmacokinetics, dual-acting, mutually-masking prodrug (DAMM), 3’-O-retinoyl-5-fluoro-2’-deoxyuridine (RFUdR), 5-fluoro-2’-deoxyuridine (FUdR), all-trans-retinoic acid (RA).
Abstract: 3’-O-Retinoyl-5-fluoro-2’-deoxyuridine (RFUdR) is a putative dual-acting, mutually-masking (DAMM) prodrug for the treatment of cancer. As part of the proof of principle for the DAMM concept, the concentrations of RFUdR and its post-hydrolysis active metabolites, 5-fluoro-2’-deoxyuridine (FUdR) and all-trans-retinoic acid (RA), were determined in plasma and selected tissues following either bolus intravenous (i.v.; 12.5 μmol/kg) or oral (p.o.; 13.7 μmol/kg) doses of RFUdR to mice bearing EMT6 murine mammary tumors. The concentrations of RFUdR and its primary metabolites were measured by high-performance liquid chromatography. A three compartment model provided the best fit for plasma RFUdR after an i.v. bolus, whereas FUdR and RA data were best fit by a one compartment model. The terminal half-life of RFUdR in plasma was 9 hours. The AUC of RFUdR in tumor (3400 μmol/Lmin) was estimated to be about 4- fold higher than its AUC in the plasma (809±241 μmol/Lmin). A short-duration, saturated elimination phase for RFUdR was observed in both liver and kidney following an i.v. bolus. Neither unchanged RFUdR nor RA was detected in urine. The high bioavailability (~90%) following oral dosing with RFUdR indicates that this DAMM prodrug may be suitable for oral dosing to deliver FUdR and RA for cancer chemotherapy.
Export Options
About this article
Cite this article as:
Xia Zuping, Knaus E. Edward and Wiebe I. Leonard, Pharmacokinetics of 3’-O-Retinoyl-5-fluoro-2’-deoxyuridine (RFUdR), a Dual Acting Mutually Masking Prodrug, and Its Metabolites in Tumor Bearing Mice, Current Drug Delivery 2013; 10 (5) . https://dx.doi.org/10.2174/15672018113109990038
DOI https://dx.doi.org/10.2174/15672018113109990038 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Safety and Side Effects of Cannabidiol, a Cannabis sativa Constituent
Current Drug Safety Editorial [Hot Topic:Targeted Therapeutics – From Chemical Structures to Diagnostic and Therapeutic Agents(Executive Editor: Christine Armbruster)]
Current Pharmaceutical Design Metabolism of Acrylamide: Interindividual and Interspecies Differences as Well as the Application as Biomarkers
Current Drug Metabolism Trophoblast Invasion: A Possible Link Between Implantation Deficiencies and Preeclampsia
Current Women`s Health Reviews Effects of Liver Diseases on Drug-metabolizing Enzymes: Implications for Drug Fate Alterations and Nano-therapeutic Openings
Current Medicinal Chemistry The Molecular Functions of Nod Proteins and their Associated Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents An Up-date of Olive Oil Phenols in Inflammation and Cancer: Molecular Mechanisms and Clinical Implications
Current Medicinal Chemistry DNA-Damaging Anticancer Drugs – A Perspective for DNA Repair- Oriented Therapy
Current Medicinal Chemistry Use of Transgenic Mice as Models for Prostate Cancer Chemoprevention
Current Molecular Medicine Randomised Trials in Surgery: The Burden of Evidence
Reviews on Recent Clinical Trials Past, Present and Future of Targeted Therapy in Solid Tumors
Current Cancer Drug Targets Role of Regulatory Oncogenic or Tumor Suppressor miRNAs of PI3K/AKT Signaling Axis in the Pathogenesis of Colorectal Cancer
Current Pharmaceutical Design ‘Treat to Target’ in Mild to Moderate Ulcerative Colitis: Evidence to Support this Strategy
Current Drug Targets Pro-Oncogenic Cell Signaling Machinery as a Target for Oncolytic Viruses
Current Pharmaceutical Biotechnology Hybrid Soft Computing Approach for Prediction of Cancer in Colon Using Microarray Gene Data
Current Signal Transduction Therapy An Overview of Compounds Derived from the Shikimate and Phenylpropanoid Pathways and Their Medicinal Importance
Mini-Reviews in Medicinal Chemistry Review: The JAK/STAT Protein Activation – Role in Cancer Development and Targeted Therapy
Current Signal Transduction Therapy Applications of Important Polysaccharides in Drug Delivery
Current Pharmaceutical Design Identification of Critical MicroRNA Gene Targets in Cervical Cancer Using Network Properties
MicroRNA Rectal Cancer in Patients Younger than 40: Tumor Characteristics and Comparative Survival Based on a Single Institution
Current Cancer Therapy Reviews